Chengdu Sibeibo Pharmaceutical Technology Co. Ltd. has divulged deuterated derivatives of taladegib acting as Hedgehog signaling inhibitors and protein smoothened (SMO) antagonists reported to be useful for the treatment of cancer and idiopathic pulmonary fibrosis.

Ascentage Pharma (Suzhou) Co. Ltd. and China Pharmaceutical University have identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to B-cell lymphoma 6 protein (BCL6)-targeting moiety through a linker reported to be useful for the treatment of cancer.

Scientists at East China Normal University and East China University of Science & Technology have synthesized 5’-nucleotidase (CD73) inhibitors reported to be useful for the treatment of cancer.

Chengdu Kangnuoxing Biopharma Inc. and Keymed Biosciences Co. Ltd. have disclosed antibody-drug conjugates (ADCs) comprising antibody or antigen binding fragments targeting cadherin-17 (CDH17) linked to a cytotoxic drug through a linker.

Shanghai Best-Link Bioscience LLC has described polymer-drug conjugates comprising a polymer covalently linked to a cytotoxic drug through a linker and its nanoparticles reported to be useful for the treatment of cancer.

Alphamol Science Ltd. has divulged opioid receptor agonists reported to be useful for the treatment of pain.

Chengdu Kangnuoxing Biopharma Inc. and Keymed Biosciences Co. Ltd. have identified antibody-drug conjugates comprising antibodies targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5; CEA; CD66e) covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.

Meta Pharmaceutical (HK) Ltd. and Shenzhen Moyuan Pharmaceuticals Co. Ltd. have synthesized lactate dehydrogenase A (LDHA) inhibitors reported to be useful for the treatment of primary hyperoxaluria.

Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has disclosed antibody-drug conjugates consisting of antibodies covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.

Immuse Therapeutics Inc. has described heterocyclic compounds acting as leucine-rich repeat kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of cancer.